Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 10/20 | 0.41 |
| ▸ | MMP12 | P39900 | 10/20 | 0.41 |
| ▸ | MMP13 | P45452 | 9/20 | 0.41 |
| ▸ | MMP14 | P50281 | 9/20 | 0.41 |
| ▸ | MMP9 | P14780 | 9/20 | 0.41 |
| ▸ | MMP8 | P22894 | 8/20 | 0.41 |
| ▸ | MMP16 | P51512 | 8/20 | 0.41 |
| ▸ | MMP1 | P03956 | 7/20 | 0.41 |
| ▸ | MMP3 | P08254 | 7/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6647677 | 0.98 | MEN1 (0.43) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL28247232 | 0.84 | MMP2 (0.41) | CYP1A2CYP3A4CYP2D6CYP2C19KMT2A | |
| SCHEMBL6069328 | 0.83 | MMP2 (0.58) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL18281576 | 0.83 | TTR (0.43) | CYP1A2MMP2MMP12MMP13MMP14 | |
| SCHEMBL4749786 | 0.83 | CA1 (0.49) | MMP2MMP12MMP13MMP14MMP9 | |
| SCHEMBL20565283 | 0.81 | MMP2 (0.41) | MMP2MMP12MMP13MMP14MMP9 | |
| SCHEMBL11324205 | 0.81 | PTGDR2 (0.45) | MMP2MMP12MMP13MMP14MMP9 | |
| SCHEMBL23174405 | 0.79 | MEN1 (0.48) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL10339218 | 0.77 | AKR1B1 (0.46) | CYP1A2CYP3A4CYP2D6CYP2C19CA2 | |
| SCHEMBL506623 | 0.76 | CYP2D6 (0.45) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321042-A1 | COMBINATION THERAPY | PFIZER INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4181919-A1 | COMBINATION THERAPY | Pfizer Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022135365-A1 | DISUBSTITUTED CYCLOPENTANE KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022018667-A1 | COMBINATION THERAPIES USING CDK2 AND CDC25A INHIBITORS | PFIZER INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| WO-2022018596-A1 | COMBINATION THERAPY | PFIZER INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| EP-2694509-A1 | PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES | Pfizer Limited (GB) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012137089-A1 | PYRROLO [2, 3 -D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES | PFIZER LIMITED (GB) | 2012-10-11 | — | — | WO | disclosed |
| EP-1572670-A1 | 5-SUBSTITUTED-PYRAZINE OR -PYRIDINE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| EP-1448525-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | AstraZeneca AB (SE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004052869-A1 | 5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-24 | — | — | WO | disclosed |
| WO-2003042178-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
| US-6414013-B1 | KINASE INHIBITORS; ANTICANCER AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321042-A1 | COMBINATION THERAPY | CDK4, CDK6, CDK2 | MEN1 1685/4885CYP1A2 2241/4885CYP3A4 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.